Short answer
BioAge Labs, Inc. (BIOA) filed its Q1 2026 10-Q quarterly report on May 8, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M (up 91.0% year over year) with net income of −$22M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- +91.0% YoY
- Net income
- −$22M
- −72.1% YoY
- Operating margin
- -915.4%
- EPS (diluted)
- −$0.52
- −44.4% YoY
Source: XBRL data from the BioAge Labs, Inc. (BIOA) Q1 2026 10-Q on SEC EDGAR. USD.
BioAge Labs, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes from the 2025 10-K; carried-forward biotechnology risks include clinical-trial failure and FDA approval delays
- Regulatory risk: product candidates require FDA and foreign approvals before commercialization
- Operational risk: dependence on third parties for product-candidate manufacturing and component materials
- Market risk: competition from substitute products and larger biotechnology companies
- Financial risk: accumulated deficit $355.7 million despite $384.9 million in cash, cash equivalents, and marketable securities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BioAge Labs, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.